<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">NPJ Precis Oncol</journal-id>
        <journal-id journal-id-type="iso-abbrev">NPJ Precis Oncol</journal-id>
        <journal-id journal-id-type="pmc-domain-id">3403</journal-id>
        <journal-id journal-id-type="pmc-domain">npjprecisoncol</journal-id>
        <journal-title-group>
          <journal-title>NPJ Precision Oncology</journal-title>
        </journal-title-group>
        <issn pub-type="epub">2397-768X</issn>
        <publisher>
          <publisher-name>Nature Publishing Group</publisher-name>
        </publisher>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC8295366</article-id>
        <article-id pub-id-type="pmcid-ver">PMC8295366.1</article-id>
        <article-id pub-id-type="pmcaid">8295366</article-id>
        <article-id pub-id-type="pmcaiid">8295366</article-id>
        <article-id pub-id-type="pmid">34290393</article-id>
        <article-id pub-id-type="doi">10.1038/s41698-021-00210-2</article-id>
        <article-id pub-id-type="publisher-id">210</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Preoperative clinical and tumor genomic features associated with pathologic lymph node metastasis in clinical stage I and II lung adenocarcinoma</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Caso</surname>
              <given-names initials="R">Raul</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Connolly</surname>
              <given-names initials="JG">James G.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Zhou</surname>
              <given-names initials="J">Jian</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Tan</surname>
              <given-names initials="KS">Kay See</given-names>
            </name>
            <xref ref-type="aff" rid="Aff3">3</xref>
            <xref ref-type="aff" rid="Aff4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6988-8648</contrib-id>
            <name name-style="western">
              <surname>Choi</surname>
              <given-names initials="JJ">James J.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4749-6528</contrib-id>
            <name name-style="western">
              <surname>Jones</surname>
              <given-names initials="GD">Gregory D.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Mastrogiacomo</surname>
              <given-names initials="B">Brooke</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Sanchez-Vega</surname>
              <given-names initials="F">Francisco</given-names>
            </name>
            <xref ref-type="aff" rid="Aff4">4</xref>
            <xref ref-type="aff" rid="Aff5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Nguyen</surname>
              <given-names initials="B">Bastien</given-names>
            </name>
            <xref ref-type="aff" rid="Aff5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Rocco</surname>
              <given-names initials="G">Gaetano</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1655-4473</contrib-id>
            <name name-style="western">
              <surname>Molena</surname>
              <given-names initials="D">Daniela</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Sihag</surname>
              <given-names initials="S">Smita</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Adusumilli</surname>
              <given-names initials="PS">Prasad S.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Bott</surname>
              <given-names initials="MJ">Matthew J.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff4">4</xref>
          </contrib>
          <contrib contrib-type="author" corresp="yes">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3318-0146</contrib-id>
            <name name-style="western">
              <surname>Jones</surname>
              <given-names initials="DR">David R.</given-names>
            </name>
            <address>
              <email>jonesd2@mskcc.org</email>
            </address>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff4">4</xref>
          </contrib>
          <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Thoracic Service, Department of Surgery, </institution><institution>Memorial Sloan Kettering Cancer Center, </institution></institution-wrap>New York, NY USA </aff>
          <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.411634.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0632 4559</institution-id><institution>Thoracic Department, Peking University People’s Hospital, </institution></institution-wrap>Beijing, China </aff>
          <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Department of Epidemiology and Biostatistics, </institution><institution>Memorial Sloan Kettering Cancer Center, </institution></institution-wrap>New York, NY USA </aff>
          <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Druckenmiller Center for Lung Cancer Research, </institution><institution>Memorial Sloan Kettering Cancer Center, </institution></institution-wrap>New York, NY USA </aff>
          <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Center for Molecular Oncology, </institution><institution>Memorial Sloan Kettering Cancer Center, </institution></institution-wrap>New York, NY USA </aff>
        </contrib-group>
        <pub-date pub-type="epub">
          <day>21</day>
          <month>7</month>
          <year>2021</year>
        </pub-date>
        <pub-date pub-type="collection">
          <year>2021</year>
        </pub-date>
        <volume>5</volume>
        <issue-id pub-id-type="pmc-issue-id">373538</issue-id>
        <elocation-id>70</elocation-id>
        <history>
          <date date-type="received">
            <day>25</day>
            <month>1</month>
            <year>2021</year>
          </date>
          <date date-type="accepted">
            <day>29</day>
            <month>6</month>
            <year>2021</year>
          </date>
        </history>
        <pub-history>
          <event event-type="pmc-release">
            <date>
              <day>21</day>
              <month>07</month>
              <year>2021</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>05</day>
              <month>08</month>
              <year>2021</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2021-08-06 00:16:27.230">
              <day>06</day>
              <month>08</month>
              <year>2021</year>
            </date>
          </event>
        </pub-history>
        <permissions>
          <copyright-statement>© The Author(s) 2021</copyright-statement>
          <license>
            <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
            <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
          </license>
        </permissions>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41698_2021_Article_210.pdf"/>
        <abstract id="Abs1">
          <p id="Par1">While next-generation sequencing (NGS) is used to guide therapy in patients with metastatic lung adenocarcinoma (LUAD), use of NGS to determine pathologic LN metastasis prior to surgery has not been assessed. To bridge this knowledge gap, we performed NGS using MSK-IMPACT in 426 treatment-naive patients with clinical N2-negative LUAD. A multivariable logistic regression model that considered preoperative clinical and genomic variables was constructed. Most patients had cN0 disease (85%) with pN0, pN1, and pN2 rates of 80%, 11%, and 9%, respectively. Genes altered at higher rates in pN-positive than in pN-negative tumors were <italic toggle="yes">STK11</italic> (<italic toggle="yes">p</italic> = 0.024), <italic toggle="yes">SMARCA4</italic> (<italic toggle="yes">p</italic> = 0.006), and <italic toggle="yes">SMAD4</italic> (<italic toggle="yes">p</italic> = 0.011). Fraction of genome altered (<italic toggle="yes">p</italic> = 0.037), copy number amplifications (<italic toggle="yes">p</italic> = 0.001), and whole-genome doubling (<italic toggle="yes">p</italic> = 0.028) were higher in pN-positive tumors. Multivariable analysis revealed solid tumor morphology, tumor SUVmax, clinical stage, <italic toggle="yes">SMARCA4</italic> and <italic toggle="yes">SMAD4</italic> alterations were independently associated with pathologic LN metastasis. Incorporation of clinical and tumor genomic features can identify patients at risk of pathologic LN metastasis; this may guide therapy decisions before surgical resection.</p>
        </abstract>
        <kwd-group kwd-group-type="npg-subject">
          <title>Subject terms</title>
          <kwd>Surgical oncology</kwd>
          <kwd>Non-small-cell lung cancer</kwd>
        </kwd-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution-wrap>
                <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000054</institution-id>
                <institution>U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI)</institution>
              </institution-wrap>
            </funding-source>
            <award-id>R01CA217169, R01CA240472, P30 CA008748</award-id>
            <award-id>T32CA009501</award-id>
            <award-id>R01CA236615</award-id>
            <principal-award-recipient>
              <name name-style="western">
                <surname>Connolly</surname>
                <given-names>James G.</given-names>
              </name>
              <name name-style="western">
                <surname>Sihag</surname>
                <given-names>Smita</given-names>
              </name>
              <name name-style="western">
                <surname>Jones</surname>
                <given-names>David R.</given-names>
              </name>
            </principal-award-recipient>
          </award-group>
        </funding-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution>Hamilton Family Foundation, Marie-Josée and Henry R. Kravis Center for Molecular Oncology</institution>
            </funding-source>
          </award-group>
        </funding-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution>U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI)</institution>
            </funding-source>
          </award-group>
        </funding-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution>U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI)</institution>
            </funding-source>
          </award-group>
        </funding-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution-wrap>
                <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000005</institution-id>
                <institution>U.S. Department of Defense (United States Department of Defense)</institution>
              </institution-wrap>
            </funding-source>
            <award-id>LC160212</award-id>
            <principal-award-recipient>
              <name name-style="western">
                <surname>Sihag</surname>
                <given-names>Smita</given-names>
              </name>
            </principal-award-recipient>
          </award-group>
        </funding-group>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>issue-copyright-statement</meta-name>
            <meta-value>© The Author(s) 2021</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
    <body>
      <sec id="Sec1" sec-type="introduction">
        <title>Introduction</title>
        <p id="Par2">Lung adenocarcinoma (LUAD) is the most common histologic subtype of non-small cell lung cancer (NSCLC)<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> and is associated with a higher risk of occult lymph node (LN) metastasis than other NSCLC tumors<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref></sup>. Combined positron emission tomography/computed tomography (PET/CT) imaging is the standard noninvasive study for LN staging<sup><xref ref-type="bibr" rid="CR4">4</xref>–<xref ref-type="bibr" rid="CR6">6</xref></sup>; however, it is associated with a high false-negative rate<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. In patients with no uptake of fluorodeoxyglucose on PET/CT, the incidence of occult mediastinal LN metastases is 7–18%<sup><xref ref-type="bibr" rid="CR8">8</xref>–<xref ref-type="bibr" rid="CR11">11</xref></sup>. In addition, PET/CT may have reduced accuracy in patients with nodes &lt;1 cm in short-axis diameter<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>, and false-positives can occur secondary to inflammation or infection<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>.</p>
        <p id="Par3">Previous studies have identified clinicopathologic variables associated with occult LN metastasis in patients with clinical N2-negative disease. These include centrally located tumors, large tumor size, high primary tumor maximum standardized uptake value (SUVmax), positive N1 nodes on PET/CT, and micropapillary histologic pattern<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup>. In clinical practice, broad-panel next-generation sequencing (NGS) has increasingly been used to elucidate tumor biology, identify targetable driver-gene perturbations, and inform prognoses for patients with NSCLC<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. To date, no study has used NGS to determine the risk of pathologic LN metastasis in patients with LUAD. Importantly, it is unknown whether this information could potentially guide the order of first line therapy (i.e., systemic vs. local) in the future. To bridge this knowledge gap, we examined tumor genomic factors in patients with clinically N2-negative (cN0-1) LUAD and assessed their association with pathologic LN metastasis identified at surgery.</p>
      </sec>
      <sec id="Sec2" sec-type="results">
        <title>Results</title>
        <sec id="Sec3">
          <title>Clinicopathologic characteristics</title>
          <p id="Par4">In total, 426 patients met the inclusion criteria; 60% (<italic toggle="yes">n</italic> = 255) were men, and 74% (<italic toggle="yes">n</italic> = 316) were current or former smokers. Clinicopathologic features are summarized in Table <xref rid="Tab1" ref-type="table">1</xref>. A majority of patients had clinical stage I disease (<italic toggle="yes">n</italic> = 334 [78%]); 22% (<italic toggle="yes">n</italic> = 92) had clinical stage II disease. On pathologic review, 80% of resected tumors (<italic toggle="yes">n</italic> = 341) were pN0 (pN-negative), and 20% (<italic toggle="yes">n</italic> = 85) were pN1 or pN2 (pN-positive). On diagnostic CT, 59% (201/341) of pN-negative tumors and 92% (78/85) of pN-positive tumors had solid morphologic appearance (<italic toggle="yes">p</italic> &lt; 0.001). Median primary tumor SUVmax was 3.5 (IQR, 1.8–6.5) for pN-negative tumors and 7.8 (IQR, 4.6–10.5) for pN-positive tumors (<italic toggle="yes">p</italic> &lt; 0.001). Invasive staging was performed in 10% of patients with clinical early-stage disease (<italic toggle="yes">n</italic> = 42)—9% underwent EBUS (<italic toggle="yes">n</italic> = 38), 0.7% underwent mediastinoscopy (<italic toggle="yes">n</italic> = 3), and 0.2% underwent both (<italic toggle="yes">n</italic> = 1).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Clinicopathologic characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Characteristic</th><th colspan="1" rowspan="1">pN-negative (<italic toggle="yes">N</italic> = 341)</th><th colspan="1" rowspan="1">pN-positive (<italic toggle="yes">N</italic> = 85)</th><th colspan="1" rowspan="1"><italic toggle="yes">p</italic></th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Age at resection, years</td><td colspan="1" rowspan="1">69 (64–74)</td><td colspan="1" rowspan="1">69 (62–74)</td><td colspan="1" rowspan="1">0.8</td></tr><tr><td colspan="4" rowspan="1">Sex</td></tr><tr><td colspan="1" rowspan="1"> Male</td><td colspan="1" rowspan="1">212 (62)</td><td colspan="1" rowspan="1">43 (51)</td><td colspan="1" rowspan="1">0.063</td></tr><tr><td colspan="1" rowspan="1"> Female</td><td colspan="1" rowspan="1">129 (38)</td><td colspan="1" rowspan="1">42 (49)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="4" rowspan="1">Smoking status</td></tr><tr><td colspan="1" rowspan="1"> Never</td><td colspan="1" rowspan="1">91 (27)</td><td colspan="1" rowspan="1">19 (22)</td><td colspan="1" rowspan="1">0.5</td></tr><tr><td colspan="1" rowspan="1"> Ever</td><td colspan="1" rowspan="1">250 (73)</td><td colspan="1" rowspan="1">66 (78)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Pack-years (<italic toggle="yes">N</italic> = 425)</td><td colspan="1" rowspan="1">16 (0–40)</td><td colspan="1" rowspan="1">20 (3.8–45)</td><td colspan="1" rowspan="1">0.2</td></tr><tr><td colspan="4" rowspan="1">Tumor morphologic appearance on CT (<italic toggle="yes">N</italic> = 423)</td></tr><tr><td colspan="1" rowspan="1"> Nonsolid</td><td colspan="1" rowspan="1">137 (41)</td><td colspan="1" rowspan="1">7 (8)</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1"> Solid</td><td colspan="1" rowspan="1">201 (59)</td><td colspan="1" rowspan="1">78 (92)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="4" rowspan="1">Tumor location</td></tr><tr><td colspan="1" rowspan="1"> RUL</td><td colspan="1" rowspan="1">110 (32)</td><td colspan="1" rowspan="1">26 (31)</td><td colspan="1" rowspan="1">0.095</td></tr><tr><td colspan="1" rowspan="1"> RML</td><td colspan="1" rowspan="1">23 (7)</td><td colspan="1" rowspan="1">2 (2)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> RLL</td><td colspan="1" rowspan="1">64 (19)</td><td colspan="1" rowspan="1">14 (16)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> LUL</td><td colspan="1" rowspan="1">84 (25)</td><td colspan="1" rowspan="1">23 (27)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> LLL</td><td colspan="1" rowspan="1">51 (15)</td><td colspan="1" rowspan="1">12 (14)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> Multiple lobes</td><td colspan="1" rowspan="1">9 (3)</td><td colspan="1" rowspan="1">8 (9)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Tumor size on CT, cm (<italic toggle="yes">N</italic> = 425)</td><td colspan="1" rowspan="1">2.2 (1.5–3)</td><td colspan="1" rowspan="1">2.9 (1.9–3.8)</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1">Tumor SUVmax (<italic toggle="yes">N</italic> = 405)</td><td colspan="1" rowspan="1">3.5 (1.8–6.5)</td><td colspan="1" rowspan="1">7.8 (4.6–10.5)</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1">cN stage (CT and PET criteria)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> cN0</td><td colspan="1" rowspan="1">308 (90)</td><td colspan="1" rowspan="1">54 (64)</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1"> cN1</td><td colspan="1" rowspan="1">33 (10)</td><td colspan="1" rowspan="1">31 (36)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="4" rowspan="1">Clinical stage</td></tr><tr><td colspan="1" rowspan="1"> I</td><td colspan="1" rowspan="1">288 (84)</td><td colspan="1" rowspan="1">46 (54)</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1"> II</td><td colspan="1" rowspan="1">53 (16)</td><td colspan="1" rowspan="1">39 (46)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="4" rowspan="1">Mediastinal staging</td></tr><tr><td colspan="1" rowspan="1"> EBUS</td><td colspan="1" rowspan="1">16 (5)</td><td colspan="1" rowspan="1">22 (26)</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1"> Mediastinoscopy</td><td colspan="1" rowspan="1">2 (0.6)</td><td colspan="1" rowspan="1">1 (1)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> EBUS and mediastinoscopy</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (1)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> None</td><td colspan="1" rowspan="1">323 (95)</td><td colspan="1" rowspan="1">61 (72)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="4" rowspan="1">Preoperative biopsy contains MIP or SOL subtype (<italic toggle="yes">N</italic> = 227)</td></tr><tr><td colspan="1" rowspan="1"> No</td><td colspan="1" rowspan="1">142 (82)</td><td colspan="1" rowspan="1">41 (77)</td><td colspan="1" rowspan="1">0.493</td></tr><tr><td colspan="1" rowspan="1"> Yes</td><td colspan="1" rowspan="1">32 (18)</td><td colspan="1" rowspan="1">12 (23)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="4" rowspan="1">pN status</td></tr><tr><td colspan="1" rowspan="1"> pN0</td><td colspan="1" rowspan="1">341 (100)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1"> pN1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">48 (56)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> pN2</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">37 (44)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="4" rowspan="1">Pathologic stage</td></tr><tr><td colspan="1" rowspan="1"> I</td><td colspan="1" rowspan="1">284 (83)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1"> II</td><td colspan="1" rowspan="1">49 (14)</td><td colspan="1" rowspan="1">42 (49)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> III</td><td colspan="1" rowspan="1">8 (2)</td><td colspan="1" rowspan="1">43 (51)</td><td colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p>Data are presented as no. (%) or median (interquartile range).</p><p><italic toggle="yes">CT</italic> computed tomography, <italic toggle="yes">EBUS</italic> endobronchial ultrasound, <italic toggle="yes">LLL</italic> left lower lobe, <italic toggle="yes">LUL</italic> left upper lobe, <italic toggle="yes">MIP</italic> micropapillary, <italic toggle="yes">PET</italic> positron emission tomography, <italic toggle="yes">RLL</italic> right lower lobe, <italic toggle="yes">RML</italic> right middle lobe, <italic toggle="yes">RUL</italic> right upper lobe, <italic toggle="yes">SOL</italic> solid.</p></table-wrap-foot></table-wrap></p>
          <p id="Par5">A median of 3 N1 stations (interquartile range [IQR], 2–3), 3 N2 stations (IQR, 2–3), and 5 total stations (IQR, 4–6) were sampled intraoperatively (Supplementary Table <xref rid="MOESM1" ref-type="media">1</xref>). Pathologic stages were as follows: 67% stage I (<italic toggle="yes">n</italic> = 284), 21% stage II (<italic toggle="yes">n</italic> = 91), and 12% stage III (<italic toggle="yes">n</italic> = 51). A total of 362 patients (85%) had cN0 disease, 15% of whom (54/362) had occult pathologic LN metastasis. In addition, 64 patients (15%) had cN1 disease, 48% of whom (31/64) had confirmed pathologic LN involvement. Occult pN2 disease was more frequently identified in patients with cN1 disease than in patients with cN0 disease (20% [13/64] vs. 7% [24/362]).</p>
        </sec>
        <sec id="Sec4">
          <title>Genomic factors associated with pathologic LN metastasis</title>
          <p id="Par6">Next, we investigated genomic factors associated with pathologic LN metastasis. Among genes altered in ≥2% of the entire cohort (<italic toggle="yes">n</italic> = 27), the most frequently altered gene in pN-negative tumors was <italic toggle="yes">KRAS</italic> (35%)—compared with 34% in pN-positive tumors (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). The most frequently altered gene in pN-positive tumors was <italic toggle="yes">TP53</italic> (45%)—compared with 34% in pN-negative tumors. Three genes were altered at significantly higher frequencies in pN-positive than in pN-negative tumors: <italic toggle="yes">STK11</italic> (22% vs. 12%; <italic toggle="yes">p</italic> = 0.024), <italic toggle="yes">SMARCA4</italic> (8% vs. 1.8%; <italic toggle="yes">p</italic> = 0.006), and <italic toggle="yes">SMAD4</italic> (7% vs. 1.5%; <italic toggle="yes">p</italic> = 0.011) (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). The alteration frequency of <italic toggle="yes">RBM10</italic> was significantly higher in pN-negative tumors than in pN-positive tumors (17% vs. 8%; <italic toggle="yes">p</italic> = 0.044) (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). These gene alterations are mainly driven by the ever-smoker cohort, as there is no statistically significant difference between pN-positive never-smokers and pN-negative never-smokers for <italic toggle="yes">STK11</italic>, <italic toggle="yes">RBM10</italic>, <italic toggle="yes">SMAD4</italic>, and <italic toggle="yes">SMARCA4</italic> (Supplementary Fig. <xref rid="MOESM1" ref-type="media">1</xref>). Interestingly, no significant differences in targetable LUAD alterations (<italic toggle="yes">n</italic> = 9) were identified (Supplementary Fig. <xref rid="MOESM1" ref-type="media">2</xref>).<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><title>OncoPrint of genes altered in ≥2% of the entire cohort according to pathologic lymph node status.</title><p>CT computed tomography, NA not available.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e1136" position="float" orientation="portrait" xlink:href="41698_2021_210_Fig1_HTML.jpg"/></fig></p>
          <p id="Par7">The distribution of tumor mutational burden (TMB) did not significantly differ between pN-negative tumors (median [IQR], 4.9 [2.6–8.8] mutations/megabase [Mb]) and pN-positive tumors (median [IQR], 6.1 [3.5–10.8] mutations/Mb; <italic toggle="yes">p</italic> = 0.058) (Fig. <xref rid="Fig2" ref-type="fig">2a</xref>). However, fraction of genome altered (FGA) was significantly higher in pN-positive tumors (median [IQR], 0.343 [0.171–0.50] vs. 0.269 [0.141–0.443]; <italic toggle="yes">p</italic> = 0.037) (Fig. <xref rid="Fig2" ref-type="fig">2b</xref>).<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><title>Summary genomic metrics according to pathologic lymph node metastasis.</title><p><bold>a</bold> Boxplot of tumor mutational burden (mutations/megabase) versus pathologic lymph node status. <bold>b</bold> Boxplot of fraction of genomic altered versus pathologic lymph node status. <bold>c</bold> Bar graphs showing percent of total tumor samples with most frequently altered mutational signatures (SBS2, SBS13, SBS4) according to pathologic lymph node metastasis (asterisk (*) signifies <italic toggle="yes">p</italic> &lt; 0.05). In the boxplots in this figure, the center line represents the median value, the bounds of the box represent the interquartile range, and the whiskers extend to 1.5× the interquartile range on either side of the median.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e1172" position="float" orientation="portrait" xlink:href="41698_2021_210_Fig2_HTML.jpg"/></fig></p>
          <p id="Par8">Additionally, we evaluated the mutational signature profiles in pN-positive and pN-negative tumors. The three most frequent signatures were the smoking signature (SBS4) and the two APOBEC signatures (SBS2 and SBS13). A statistically significantly higher percentage of pN-positive tumors (SBS2 27.3%; SBS13 31.8%) had APOBEC signatures present, compared with pN-negative tumors (SBS2 12.8%; SBS13 14.9%). Both SBS2 (<italic toggle="yes">p</italic> = 0.03) and SBS13 (<italic toggle="yes">p</italic> = 0.02) were statistically significantly more enriched in pN-positive tumors. There was no statistically significant difference in smoking signatures between the two groups (Fig. <xref rid="Fig2" ref-type="fig">2c</xref>).</p>
        </sec>
        <sec id="Sec5">
          <title>Copy number alterations associated with pathologic LN metastasis</title>
          <p id="Par9">To further examine our observation that pN-positive tumors had significantly higher FGA, we next investigated the copy number landscape (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). No significant differences in tumor purity were identified between pN-negative and pN-positive tumors (<italic toggle="yes">p</italic> = 0.059) (Supplementary Fig. <xref rid="MOESM1" ref-type="media">3A</xref>). Copy number amplifications were significantly higher in pN-positive tumors than in pN-negative tumors (median [IQR], 0.152 [0.060–0.314] vs. 0.085 [0.037–0.208]; <italic toggle="yes">p</italic> = 0.001) (Fig. <xref rid="Fig3" ref-type="fig">3a</xref>). Copy number deletions were not significantly different between groups (<italic toggle="yes">p</italic> = 0.299) (Fig. <xref rid="Fig3" ref-type="fig">3b</xref>). Significant differences in chromosome arm-level copy number (false-discovery rate [FDR] <italic toggle="yes">p</italic> &lt; 0.2) between pN-negative and pN-positive tumors were identified at 2p (<italic toggle="yes">p</italic> = 0.122) and 2q (<italic toggle="yes">p</italic> = 0.122), where both arms exhibit more copy number changes in pN-positive tumors (Fig. <xref rid="Fig3" ref-type="fig">3c</xref>). The copy number changes observed were broad, and no focal copy number changes were observed on chromosome 2 in either pN-positive or pN-negative tumors.<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><title>Copy number alteration analysis according to pathologic lymph node metastasis.</title><p><bold>a</bold> Boxplot of copy number amplifications versus pathologic lymph node status. <bold>b</bold> Boxplot of copy number deletions versus pathologic lymph node status. <bold>c</bold> Comparison of copy number alterations across chromosome arms according to pathologic lymph node status. <bold>d</bold> Bar plot of the rate of whole-genome doubling versus pathologic lymph node status. In the boxplots in this figure, the center line represents the median value, the bounds of the box represent the interquartile range, and the whiskers extend to 1.5× the interquartile range on either side of the median.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e1245" position="float" orientation="portrait" xlink:href="41698_2021_210_Fig3_HTML.jpg"/></fig></p>
          <p id="Par10">Genes with copy number alterations present in ≥1% of the entire cohort (<italic toggle="yes">n</italic> = 14 genes; Supplementary Fig. <xref rid="MOESM1" ref-type="media">3B</xref>) were also evaluated. Among pN-positive tumors, <italic toggle="yes">CDKN2A</italic> was the most frequently altered (9%), whereas <italic toggle="yes">MDM2</italic> was most frequently altered (10%) among pN-negative tumors. <italic toggle="yes">CDK4</italic> was altered significantly more often in pN-negative tumors than in pN-positive tumors (8% vs. 1.2%; <italic toggle="yes">p</italic> = 0.029) (Supplementary Fig. <xref rid="MOESM1" ref-type="media">3B</xref>), and <italic toggle="yes">CDKN2A</italic> was altered significantly more often in pN-positive tumors than in pN-negative tumors (9% vs. 4%; <italic toggle="yes">p</italic> = 0.039) (Supplementary Fig. <xref rid="MOESM1" ref-type="media">3B</xref>). Finally, pN-positive tumors had a higher rate of whole-genome doubling (WGD; 22% vs. 13%; <italic toggle="yes">p</italic> = 0.028) (Fig. <xref rid="Fig3" ref-type="fig">3d</xref>), further elucidating their chromosomal instability.</p>
        </sec>
        <sec id="Sec6">
          <title>Preoperative clinicopathologic and genomic features associated with pathologic LN metastasis</title>
          <p id="Par11">Next, we performed logistic regression analyses to identify clinicopathologic and genomic features associated with pathologic LN metastasis. Univariable logistic regression analysis identified the following preoperative clinicopathologic variables (Supplementary Table <xref rid="MOESM1" ref-type="media">2</xref>): solid versus nonsolid tumor morphologic appearance on CT (<italic toggle="yes">p</italic> &lt; 0.001), tumor size on CT (<italic toggle="yes">p</italic> = 0.001), tumor SUVmax (<italic toggle="yes">p</italic> &lt; 0.001), cN1 versus cN0 (<italic toggle="yes">p</italic> &lt; 0.001), and clinical stage II versus I (<italic toggle="yes">p</italic> &lt; 0.001). We then performed clinical stage-adjusted univariable logistic regression analyses to identify genomic variables associated with pathologic LN metastasis (Supplementary Table <xref rid="MOESM1" ref-type="media">3</xref>). The following genomic variables were considered in the final multivariable model: WGD (<italic toggle="yes">p</italic> = 0.014), copy number amplifications (<italic toggle="yes">p</italic> = 0.002), <italic toggle="yes">STK11</italic> alteration versus wild-type (<italic toggle="yes">p</italic> = 0.026), <italic toggle="yes">SMARCA4</italic> alteration versus wild-type (<italic toggle="yes">p</italic> = 0.013), and <italic toggle="yes">SMAD4</italic> alteration versus wild-type (<italic toggle="yes">p</italic> = 0.004).</p>
          <p id="Par12">On multivariable regression analysis combining preoperative clinicopathologic and genomic features, the following variables were independently associated with pathologic LN metastasis (Fig. <xref rid="Fig4" ref-type="fig">4</xref>): solid versus nonsolid tumor morphologic appearance on CT (odds ratio [OR], 4.25; 95% confidence interval [CI], 1.81–9.93; <italic toggle="yes">p</italic> = 0.001), tumor SUVmax (OR, 1.09; 95% CI, 1.03–1.15; <italic toggle="yes">p</italic> = 0.002), clinical stage II versus I (OR, 3.31; 95% CI, 1.87–5.88; <italic toggle="yes">p</italic> &lt; 0.001), <italic toggle="yes">SMARCA4</italic> alteration versus wild-type (OR, 3.67; 95% CI, 1.02–13.16; <italic toggle="yes">p</italic> = 0.046), and <italic toggle="yes">SMAD4</italic> alteration versus wild-type (OR, 5.01; 95% CI, 1.29–19.45; <italic toggle="yes">p</italic> = 0.02).<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><title>Multivariable logistic regression model of preoperative clinicopathologic and genomic features associated with pathologic lymph node metastasis.</title><p>In the forest plot in this figure, the points represent the odds ratio, and the whiskers represent the confidence interval corresponding to the table to the right. CI confidence interval, CT computed tomography, OR odds ratio, SUV standardized uptake value.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e1375" position="float" orientation="portrait" xlink:href="41698_2021_210_Fig4_HTML.jpg"/></fig></p>
        </sec>
        <sec id="Sec7">
          <title>Association between copy number amplifications and clinicopathologic characteristics</title>
          <p id="Par13">To further examine the association between copy number amplifications and pathologic LN metastasis in the clinical stage-adjusted analysis of genomic variables above, we investigated the relationship between copy number amplification tertiles (low vs. intermediate vs. high) and select clinicopathologic characteristics. Significant associations between copy number amplification tertiles and preoperative clinical characteristics (tumor size on CT, tumor solid morphologic appearance on CT, and primary tumor SUVmax) were identified; copy number amplification tertiles were also shown to be associated with pathologic characteristics obtained from the surgical specimen (pathologic tumor size, micropapillary- or solid-predominant histologic subtype, visceral pleural invasion, lymphovascular invasion, tumor spread through air spaces, pathologic LN metastasis, and pathologic stage) (Supplementary Fig. <xref rid="MOESM1" ref-type="media">4</xref>).</p>
        </sec>
      </sec>
      <sec id="Sec8" sec-type="discussion">
        <title>Discussion</title>
        <p id="Par14">The ability to better predict pathologic LN metastasis would allow the identification of subgroups of patients who may benefit from neoadjuvant therapy before tumor resection. In the present study, we found that, of 362 patients with cN0 disease, 15% (<italic toggle="yes">n</italic> = 54) had pathologic LN metastasis at the time of surgery. This results in a false-negative rate (proportion of pN-positive patients who had cN0 disease) of 64% for preoperative clinical LN staging. To address the limitations of radiographic nodal assessment and staging, we analyzed tumor genomic features as well as clinical and radiographic features to determine variables that are independently associated with pathologic LN metastasis in patients with clinical stage I/II LUAD.</p>
        <p id="Par15">Multiple studies have identified radiographic and pathologic predictors of occult LN metastasis, including SUVmax<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>, lymphatic invasion<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>, vascular invasion<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>, and micropapillary histologic pattern<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Most of these studies used data that can be reliably obtained only from the pathologic specimen; the utility of such data for preoperative or intraoperative decision-making is therefore limited. Our group previously reported that frozen section analysis can be used to detect micropapillary histologic patterns<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>, the results of which can guide intraoperative decision-making. More recently, we demonstrated that the presence of tumor spread through air spaces on frozen section analysis is an independent predictor of occult pathologic LN metastasis<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. However, the challenge with the use of pathologic predictors obtained from intraoperative frozen sections or the surgical specimen is that such features are not applicable to preoperative clinical decision-making. Recently, Verdial and colleagues, in a study of patients with clinical stage I-IIIB NSCLC, reported a prediction model that used only radiographic variables and had a bias-corrected C-index of 0.78<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>.</p>
        <p id="Par16">During the last decade, NGS has changed the clinician’s approach to the management of NSCLC<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. The model developed here combines clinical variables available preoperatively (tumor morphologic appearance on CT, tumor SUVmax, and clinical stage) and genomic data (<italic toggle="yes">SMAD4</italic> and <italic toggle="yes">SMARCA4</italic> alterations) that can be obtained from a preoperative biopsy specimen to better guide the therapeutic strategy. A similar methodology has recently been used to individualize therapy for patients with melanoma<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>.</p>
        <p id="Par17">We evaluated various genomic summary metrics, such as TMB and FGA, as well as individual gene alterations for inclusion in the final pathologic LN metastasis prediction model. Alterations in <italic toggle="yes">SMAD4</italic> and <italic toggle="yes">SMARCA4</italic> were independently associated with pathologic LN metastasis. Both <italic toggle="yes">SMAD4</italic> and <italic toggle="yes">SMARCA4</italic> were altered at significant rates in tumors from patients with pathologic LN metastasis. <italic toggle="yes">SMAD4</italic> mediates signaling of transforming growth factor beta and bone morphogenic protein ligands, and it is a well-defined tumor suppressor in pancreatic and colon cancer<sup><xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR22">22</xref></sup>. Reduced <italic toggle="yes">SMAD4</italic> expression in NSCLC has been associated with increased DNA damage, reduced DNA repair, and increased sensitivity to topoisomerase inhibitors<sup><xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR24">24</xref></sup>. <italic toggle="yes">SMARCA4</italic> is a subunit of the switch/sucrose nonfermentable (SWI/SNF) complex, which plays important roles in chromatin remodeling and, thus, in the regulation of vital cellular processes and functions, such as gene expression, proliferation, and differentiation<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. In lung cancer, <italic toggle="yes">SMARCA4</italic> inactivation is the most common alteration within the SWI/SNF complex and has been associated with poor oncologic outcomes<sup><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup>. Recently, Schoenfeld and colleagues reported that <italic toggle="yes">SMARCA4</italic> alterations co-occurred more frequently with <italic toggle="yes">KRAS</italic>, <italic toggle="yes">STK11</italic>, and <italic toggle="yes">KEAP1</italic> mutations, compared with <italic toggle="yes">SMARCA4</italic> wild-type tumors<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. Interestingly, they also identified improved outcomes after treatment with immunotherapy in patients with <italic toggle="yes">SMARCA4</italic>-mutant tumors<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup>.</p>
        <p id="Par18">We also investigated the genomic landscape of tumors from patients with pathologic LN metastasis and patients without pathologic LN metastasis. Alteration rates of <italic toggle="yes">STK11</italic>, <italic toggle="yes">SMARCA4</italic>, and <italic toggle="yes">SMAD4</italic> were significantly higher among tumors from patients with pathologic LN metastasis, consistent with prior findings<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. In our cohort, the increased alteration rates are mainly driven by the ever-smoker subgroup, as these genes are not frequently altered in the never-smokers. This is likely caused by the small sample size of never-smokers, especially pN-positive never-smokers, and the lower TMB burden in the never-smokers (Supplementary Fig. <xref rid="MOESM1" ref-type="media">1</xref>). A more comprehensive investigation with larger numbers of never-smoker patients is needed to assess differences between pN-positive ever-smokers and never-smokers.</p>
        <p id="Par19">FGA and copy number amplifications were also statistically significantly higher among tumors from patients with pathologic LN metastasis. FGA is a surrogate for chromosome instability, which has been shown to promote tumor metastasis through the activation of the cGAS-STING pathway<sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup>. FGA has been shown to correlate with survival in other cancers<sup><xref ref-type="bibr" rid="CR32">32</xref>–<xref ref-type="bibr" rid="CR36">36</xref></sup>. A higher level of subclonal copy number alterations has been associated with poorer disease-free survival in patients with resected early-stage NSCLC<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>.</p>
        <p id="Par20">Additionally, we found an enrichment in APOBEC signatures in pN-positive tumors. The APOBEC signatures have been shown to contribute to increased tumor heterogeneity in both primary<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> and metastatic NSCLC tumors<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. These findings have important clinical implications, as APOBEC signatures have the potential to predict immune response, which may serve as a potential marker for immunotherapy in pN-positive patients<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>.</p>
        <p id="Par21">Interestingly, we found an association between copy number amplifications and pathologic LN metastasis on univariable analysis, which prompted us to further investigate the relationship between copy number amplification and clinicopathologic variables. We identified a significant relationship between high copy number amplification tertiles and various poor clinicopathologic indicators. Finally, as further evidence of their more aggressive nature, tumors from patients with pathologic LN metastasis were associated with a higher rate of WGD, which has been associated with poor long-term survival across multiple cancers<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>.</p>
        <p id="Par22">This study has several limitations. NGS was performed using single-region sampling of the primary tumor. As previously noted, intratumoral heterogeneity is intrinsic to LUAD<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>, and single-region sampling may not accurately capture the complexity of the disease, such as its clonal architecture<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. In addition, tumor genomic analyses were performed on the surgical specimen, not on preoperative biopsy specimens. Obtaining high-quality DNA for NGS from biopsy specimens can be a challenge<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>, but success rates of 80–90% are now being reported for small tumor tissue samples obtained from CT-guided and bronchoscopic biopsies—convincingly demonstrating that acquisition of adequate quality DNA for NGS is possible before surgical resection<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. Our final model incorporates <italic toggle="yes">SMARCA4</italic> and <italic toggle="yes">SMAD4</italic> alterations; however, similar to many other genomic drivers of aggressive tumor biology, the frequency of these alterations is modest, especially in never-smokers<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. Finally, external validation is required to evaluate the performance of the model.</p>
        <p id="Par23">In summary, this study highlights the potential importance of genomic data for identification of patients at risk of pathologic LN metastasis. Although clinical stage remains important for identifying patients at risk of pathologic LN metastasis, in isolation it does not perform well in the prediction of nodal disease in this early-stage LUAD cohort. Our final multivariable model comprised preoperative clinical features and <italic toggle="yes">SMARCA4</italic> and <italic toggle="yes">SMAD4</italic> alteration data that were found to be independently associated with pathologic LN metastasis. The ability to identify patients with stage I/III LUAD who are at high risk of pathologic LN metastasis could potentially guide the therapeutic strategy prior to surgical resection.</p>
      </sec>
      <sec id="Sec9">
        <title>Methods</title>
        <sec id="Sec10">
          <title>Patient cohort</title>
          <p id="Par24">This study was approved by the institutional review board at Memorial Sloan Kettering Cancer Center. All patients provided written informed consent to participate in the institutional review board–approved protocol. Patients included in the study underwent complete resection for LUAD and had NGS (Memorial Sloan Kettering–Integrated Mutation Profiling of Actionable Cancer Targets [MSK-IMPACT]<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>) performed on their primary tumor between 2010 and 2018. All patients received an anatomic resection (lobectomy, segmentectomy, or pneumonectomy) with LN dissection. Exclusion criteria included induction therapy, wedge resection, microscopic or macroscopic residual disease (R1/R2 resection), and low-quality NGS. Patients included in the study were grouped according to pathologic LN metastasis (see CONSORT diagram, Supplementary Fig. <xref rid="MOESM1" ref-type="media">5</xref>). pN1 and pN2 patients were grouped together as there were no statistically significant differences in gene frequency alterations between pN1 and pN2 patients.</p>
          <p id="Par25">Clinical characteristics, preoperative CT and PET, and pathology reports (adjusted according to the 8th edition of the AJCC Cancer Staging Manual) were reviewed. Tumor size, presence of solid tumor morphologic appearance, primary tumor SUVmax, and lymphadenopathy (documented as such or ≥1 cm in short axis on CT scan<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>) were recorded. Follow-up was performed in accordance with National Comprehensive Cancer Network guidelines<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>.</p>
        </sec>
        <sec id="Sec11">
          <title>Tumor genomic analysis</title>
          <p id="Par26">MSK-IMPACT sequencing was performed and analyzed as previously described<sup><xref ref-type="bibr" rid="CR46">46</xref>,<xref ref-type="bibr" rid="CR48">48</xref></sup>. TMB was defined as the fraction of nonsynonymous single-nucleotide or insertion/deletion mutations divided by the length of the coding region (in Mb) sequenced by each panel (0.98, 1.06, and 1.22 Mb in the 341-, 410-, and 468-gene panels, respectively). FGA was computed from the output of Fraction and Allele-Specific Copy Number Estimates from Tumor Sequencing (FACETS), which provides accurate, purity- and ploidy-corrected, integer DNA copy number calls from sequenced samples. FGA is defined as the fraction of the genome that differs from the major integer copy number (MCN), which is defined as the integer total copy number spanning the largest portion of the genome<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>.</p>
          <p id="Par27">Copy number alteration frequency plots were generated using the Integrative Genomics Viewer from Broad Institute. Significant focal copy number alterations were identified from segmented data using GISTIC 2.0<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>. Copy number deletions, amplifications, WGD, and arm-level FGA estimates were calculated from the FACETS method output<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>. Copy number amplifications were defined as the fraction of the genome that was greater than the MCN, whereas copy number deletions were defined as the fraction of the genome that was less than the MCN. Tumor samples were considered to have undergone WGD if &gt;50% of their autosomal genome had an MCN (the more frequent allele in a given segment) &gt;2. Arm-level FGA was defined as the fraction of the chromosomal arm that differed from the MCN. <italic toggle="yes">p</italic>-values highlighting differences in arm-level FGA between histologic subtypes were calculated using the Kruskal–Wallis test and were adjusted for multiple comparisons using the FDR method; FDR <italic toggle="yes">p</italic> &lt; 0.2 was considered significant.</p>
          <p id="Par28">Mutational signatures were computed<sup><xref ref-type="bibr" rid="CR51">51</xref></sup> for samples with at least 13.8 Mut/Mb, as described by Zehir et al.<sup><xref ref-type="bibr" rid="CR52">52</xref></sup> (pN-positive [<italic toggle="yes">n</italic> = 44] and pN-negative [<italic toggle="yes">n</italic> = 141]). We used the most recent version of the single base substitution signatures defined in the Catalogue of Somatic Mutations in Cancer database<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>. Samples were considered to have a signature present if the mean signature value was greater than 0.1.</p>
        </sec>
        <sec id="Sec12">
          <title>Statistical analysis</title>
          <p id="Par29">The Chi-square test and Mann–Whitney U-test were used to compare the categorical and continuous factors between the two patient cohorts (pN-negative [pN0] vs. pN-positive [pN1/pN2]), respectively. Fisher’s exact test was used to compare the alteration frequencies of genes altered in ≥2% of the entire cohort. Univariable logistic regression analysis was performed to quantify the relationships between preoperative clinicopathologic features and pathologic LN metastasis. A separate univariable logistic regression analysis, adjusted for clinical stage, was performed to quantify the relationships between genomic features and pathologic LN metastasis. A multivariable logistic regression model was constructed starting with preoperative clinicopathologic and genomic factors with <italic toggle="yes">p</italic> &lt; 0.1 in univariable analyses in a backward-selection method. All analyses were two-sided, and <italic toggle="yes">p</italic> &lt; 0.05 was considered to indicate statistical significance. All analyses were performed using Stata 15.0 (StataCorp, College Station, TX) and R 3.5.3 (R Core Team, Vienna, Austria).</p>
        </sec>
        <sec id="Sec13">
          <title>Reporting summary</title>
          <p id="Par30">Further information on research design is available in the <xref rid="MOESM2" ref-type="media">Nature Research Reporting Summary</xref> linked to this article.</p>
        </sec>
      </sec>
      <sec sec-type="supplementary-material">
        <title>Supplementary information</title>
        <sec id="Sec14">
          <supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait">
            <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41698_2021_210_MOESM1_ESM.pdf" position="float" orientation="portrait">
              <caption>
                <p>Supplementary Information</p>
              </caption>
            </media>
          </supplementary-material>
          <supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait">
            <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41698_2021_210_MOESM2_ESM.pdf" position="float" orientation="portrait">
              <caption>
                <p>Reporting Summary</p>
              </caption>
            </media>
          </supplementary-material>
        </sec>
      </sec>
    </body>
    <back>
      <fn-group>
        <fn>
          <p><bold>Publisher’s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
        </fn>
      </fn-group>
      <sec>
        <title>Supplementary information</title>
        <p>The online version contains supplementary material available at 10.1038/s41698-021-00210-2.</p>
      </sec>
      <ack>
        <title>Acknowledgements</title>
        <p>We gratefully acknowledge the members of the Molecular Diagnostics Service in the Department of Pathology. David B. Sewell, of the MSK Department of Surgery, provided superb editorial assistance. This study was supported by the National Cancer Institute (R01CA217169 and R01CA240472 to D.R.J., R01CA236615 to P.S.A., T32CA009501 to J.G.C., P30 CA008748 to Memorial Sloan Kettering Cancer Center), Hamilton Family Foundation (to D.R.J.), and Department of Defense (LC160212 to P.S.A.). This work was funded in part by the Marie-Josée and Henry R. Kravis Center for Molecular Oncology.</p>
      </ack>
      <notes notes-type="author-contribution">
        <title>Author contributions</title>
        <p>D.R.J. conceived the project and supervised the study. R.C. performed data acquisition, annotation, analysis, interpretation, figure preparation, and manuscript preparation. J.C., B.M., F.S.V., and B.N. assisted with bioinformatics analysis, figure design, and data analysis. K.S.T. performed the statistical analyses. G.J., G.R., D.M., P.A., S.S., and M.B. provided critical feedback and helped to shape and finalize the manuscript. All co-authors agreed to the final version of the manuscript.</p>
      </notes>
      <notes notes-type="data-availability">
        <title>Data availability</title>
        <p>All the genomic and clinical data used in our analyses are publicly available through the cBioPortal for Cancer Genomics<sup><xref ref-type="bibr" rid="CR54">54</xref></sup> at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cbioportal.org/study/summary?id=luad_msk_npjpo_2021">https://www.cbioportal.org/study/summary?id=luad_msk_npjpo_2021</ext-link>.</p>
      </notes>
      <notes id="FPar1" notes-type="COI-statement">
        <title>Competing interests</title>
        <p id="Par31">G.R. has financial relationships with Scanlan. D.M. is a consultant for Johnson &amp; Johnson, Urogen, Intuitive, and Boston Scientific. P.S.A. has received research funding from ATARA Biotherapeutics and Acea Biosciences, has served on the Scientific Advisory Board or as consultant to ATARA Biotherapeutics, Bayer, Carisma Therapeutics, Imugene, and Takeda Therapeutics, and has patents, royalties, and intellectual property on mesothelin-targeted CARs and other T-cell therapies, method for detection of cancer cells using virus, and pending patent applications on T-cell therapies. M.J.B. serves as a consultant for AstraZeneca. D.R.J. serves as a consultant for AstraZeneca and is on a Clinical Trial Steering Committee for Merck. All other authors have no potential conflicts to disclose.</p>
      </notes>
      <ref-list id="Bib1">
        <title>References</title>
        <ref id="CR1">
          <label>1.</label>
          <mixed-citation publication-type="other">Howlader, N. et al. <italic toggle="yes">SEER Cancer Statistics Review, 1975–2016</italic>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://seer.cancer.gov/csr/1975_2016/">https://seer.cancer.gov/csr/1975_2016/</ext-link>. (2020).</mixed-citation>
        </ref>
        <ref id="CR2">
          <label>2.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Bille</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Woo</surname>
                <given-names>KM</given-names>
              </name>
              <name name-style="western">
                <surname>Ahmad</surname>
                <given-names>U</given-names>
              </name>
              <name name-style="western">
                <surname>Rizk</surname>
                <given-names>NP</given-names>
              </name>
              <name name-style="western">
                <surname>Jones</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Incidence of occult pN2 disease following resection and mediastinal lymph node dissection in clinical stage I lung cancer patients</article-title>
            <source>Eur. J. Cardiothorac. Surg.</source>
            <year>2017</year>
            <volume>51</volume>
            <fpage>674</fpage>
            <lpage>679</lpage>
            <pub-id pub-id-type="doi">10.1093/ejcts/ezw400</pub-id>
            <pub-id pub-id-type="pmid">28200091</pub-id>
            <pub-id pub-id-type="pmcid">PMC5848815</pub-id>
          </element-citation>
        </ref>
        <ref id="CR3">
          <label>3.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Suzuki</surname>
                <given-names>K</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Clinical predictors of N2 disease in the setting of a negative computed tomographic scan in patients with lung cancer</article-title>
            <source>J. Thorac. Cardiovasc. Surg.</source>
            <year>1999</year>
            <volume>117</volume>
            <fpage>593</fpage>
            <lpage>598</lpage>
            <pub-id pub-id-type="doi">10.1016/S0022-5223(99)70340-5</pub-id>
            <pub-id pub-id-type="pmid">10047665</pub-id>
          </element-citation>
        </ref>
        <ref id="CR4">
          <label>4.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Fischer</surname>
                <given-names>B</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Preoperative staging of lung cancer with combined PET-CT</article-title>
            <source>N. Engl. J. Med</source>
            <year>2009</year>
            <volume>361</volume>
            <fpage>32</fpage>
            <lpage>39</lpage>
            <pub-id pub-id-type="doi">10.1056/NEJMoa0900043</pub-id>
            <pub-id pub-id-type="pmid">19571281</pub-id>
          </element-citation>
        </ref>
        <ref id="CR5">
          <label>5.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Lardinois</surname>
                <given-names>D</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography</article-title>
            <source>N. Engl. J. Med.</source>
            <year>2003</year>
            <volume>348</volume>
            <fpage>2500</fpage>
            <lpage>2507</lpage>
            <pub-id pub-id-type="doi">10.1056/NEJMoa022136</pub-id>
            <pub-id pub-id-type="pmid">12815135</pub-id>
          </element-citation>
        </ref>
        <ref id="CR6">
          <label>6.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Shim</surname>
                <given-names>SS</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging</article-title>
            <source>Radiology</source>
            <year>2005</year>
            <volume>236</volume>
            <fpage>1011</fpage>
            <lpage>1019</lpage>
            <pub-id pub-id-type="doi">10.1148/radiol.2363041310</pub-id>
            <pub-id pub-id-type="pmid">16014441</pub-id>
          </element-citation>
        </ref>
        <ref id="CR7">
          <label>7.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Lv</surname>
                <given-names>YL</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Diagnostic performance of integrated positron emission tomography/computed tomography for mediastinal lymph node staging in non-small cell lung cancer: a bivariate systematic review and meta-analysis</article-title>
            <source>J. Thorac. Oncol.</source>
            <year>2011</year>
            <volume>6</volume>
            <fpage>1350</fpage>
            <lpage>1358</lpage>
            <pub-id pub-id-type="doi">10.1097/JTO.0b013e31821d4384</pub-id>
            <pub-id pub-id-type="pmid">21642874</pub-id>
          </element-citation>
        </ref>
        <ref id="CR8">
          <label>8.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Kanzaki</surname>
                <given-names>R</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Occult mediastinal lymph node metastasis in NSCLC patients diagnosed as clinical N0-1 by preoperative integrated FDG-PET/CT and CT: Risk factors, pattern, and histopathological study</article-title>
            <source>Lung Cancer</source>
            <year>2011</year>
            <volume>71</volume>
            <fpage>333</fpage>
            <lpage>337</lpage>
            <pub-id pub-id-type="doi">10.1016/j.lungcan.2010.06.008</pub-id>
            <pub-id pub-id-type="pmid">20619479</pub-id>
          </element-citation>
        </ref>
        <ref id="CR9">
          <label>9.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Yeh</surname>
                <given-names>YC</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification predicts occult lymph node metastasis in clinically mediastinal node-negative lung adenocarcinoma</article-title>
            <source>Eur. J. Cardiothorac. Surg.</source>
            <year>2016</year>
            <volume>49</volume>
            <fpage>e9</fpage>
            <lpage>e15</lpage>
            <pub-id pub-id-type="doi">10.1093/ejcts/ezv316</pub-id>
            <pub-id pub-id-type="pmid">26377636</pub-id>
            <pub-id pub-id-type="pmcid">PMC4678972</pub-id>
          </element-citation>
        </ref>
        <ref id="CR10">
          <label>10.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Gomez-Caro</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Incidence of occult mediastinal node involvement in cN0 non-small-cell lung cancer patients after negative uptake of positron emission tomography/computer tomography scan</article-title>
            <source>Eur. J. Cardiothorac. Surg.</source>
            <year>2010</year>
            <volume>37</volume>
            <fpage>1168</fpage>
            <lpage>1174</lpage>
            <pub-id pub-id-type="doi">10.1016/j.ejcts.2009.12.013</pub-id>
            <pub-id pub-id-type="pmid">20116273</pub-id>
          </element-citation>
        </ref>
        <ref id="CR11">
          <label>11.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Veeramachaneni</surname>
                <given-names>NK</given-names>
              </name>
              <name name-style="western">
                <surname>Battafarano</surname>
                <given-names>RJ</given-names>
              </name>
              <name name-style="western">
                <surname>Meyers</surname>
                <given-names>BF</given-names>
              </name>
              <name name-style="western">
                <surname>Zoole</surname>
                <given-names>JB</given-names>
              </name>
              <name name-style="western">
                <surname>Patterson</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for occult nodal metastasis in clinical T1N0 lung cancer: a negative impact on survival</article-title>
            <source>Eur. J. Cardiothorac. Surg.</source>
            <year>2008</year>
            <volume>33</volume>
            <fpage>466</fpage>
            <lpage>469</lpage>
            <pub-id pub-id-type="doi">10.1016/j.ejcts.2007.12.015</pub-id>
            <pub-id pub-id-type="pmid">18249130</pub-id>
          </element-citation>
        </ref>
        <ref id="CR12">
          <label>12.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Lu</surname>
                <given-names>P</given-names>
              </name>
              <name name-style="western">
                <surname>Sun</surname>
                <given-names>Y</given-names>
              </name>
              <name name-style="western">
                <surname>Sun</surname>
                <given-names>Y</given-names>
              </name>
              <name name-style="western">
                <surname>Yu</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The role of (18)F-FDG PET/CT for evaluation of metastatic mediastinal lymph nodes in patients with lung squamous-cell carcinoma or adenocarcinoma</article-title>
            <source>Lung Cancer</source>
            <year>2014</year>
            <volume>85</volume>
            <fpage>53</fpage>
            <lpage>58</lpage>
            <pub-id pub-id-type="doi">10.1016/j.lungcan.2014.04.004</pub-id>
            <pub-id pub-id-type="pmid">24792334</pub-id>
          </element-citation>
        </ref>
        <ref id="CR13">
          <label>13.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Tsim</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>O’Dowd</surname>
                <given-names>CA</given-names>
              </name>
              <name name-style="western">
                <surname>Milroy</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Davidson</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Staging of non-small cell lung cancer (NSCLC): a review</article-title>
            <source>Respir. Med</source>
            <year>2010</year>
            <volume>104</volume>
            <fpage>1767</fpage>
            <lpage>1774</lpage>
            <pub-id pub-id-type="doi">10.1016/j.rmed.2010.08.005</pub-id>
            <pub-id pub-id-type="pmid">20833010</pub-id>
          </element-citation>
        </ref>
        <ref id="CR14">
          <label>14.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Farjah</surname>
                <given-names>F</given-names>
              </name>
              <name name-style="western">
                <surname>Lou</surname>
                <given-names>F</given-names>
              </name>
              <name name-style="western">
                <surname>Sima</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Rusch</surname>
                <given-names>VW</given-names>
              </name>
              <name name-style="western">
                <surname>Rizk</surname>
                <given-names>NP</given-names>
              </name>
            </person-group>
            <article-title>A prediction model for pathologic N2 disease in lung cancer patients with a negative mediastinum by positron emission tomography</article-title>
            <source>J. Thorac. Oncol.</source>
            <year>2013</year>
            <volume>8</volume>
            <fpage>1170</fpage>
            <lpage>1180</lpage>
            <pub-id pub-id-type="doi">10.1097/JTO.0b013e3182992421</pub-id>
            <pub-id pub-id-type="pmid">23945387</pub-id>
          </element-citation>
        </ref>
        <ref id="CR15">
          <label>15.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Verdial</surname>
                <given-names>FC</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Prediction model for nodal disease among patients with non-small cell lung cancer</article-title>
            <source>Ann. Thorac. Surg.</source>
            <year>2019</year>
            <volume>107</volume>
            <fpage>1600</fpage>
            <lpage>1606</lpage>
            <pub-id pub-id-type="doi">10.1016/j.athoracsur.2018.12.041</pub-id>
            <pub-id pub-id-type="pmid">30710518</pub-id>
            <pub-id pub-id-type="pmcid">PMC6535349</pub-id>
          </element-citation>
        </ref>
        <ref id="CR16">
          <label>16.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Korf</surname>
                <given-names>BR</given-names>
              </name>
              <name name-style="western">
                <surname>Rehm</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>New approaches to molecular diagnosis</article-title>
            <source>JAMA</source>
            <year>2013</year>
            <volume>309</volume>
            <fpage>1511</fpage>
            <lpage>1521</lpage>
            <pub-id pub-id-type="doi">10.1001/jama.2013.3239</pub-id>
            <pub-id pub-id-type="pmid">23571590</pub-id>
          </element-citation>
        </ref>
        <ref id="CR17">
          <label>17.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Moon</surname>
                <given-names>Y</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Clinicopathologic factors associated with occult lymph node metastasis in patients with clinically diagnosed n0 lung adenocarcinoma</article-title>
            <source>Ann. Thorac. Surg.</source>
            <year>2016</year>
            <volume>101</volume>
            <fpage>1928</fpage>
            <lpage>1935</lpage>
            <pub-id pub-id-type="doi">10.1016/j.athoracsur.2015.11.056</pub-id>
            <pub-id pub-id-type="pmid">26952299</pub-id>
          </element-citation>
        </ref>
        <ref id="CR18">
          <label>18.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Yeh</surname>
                <given-names>YC</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Using frozen section to identify histological patterns in stage I lung adenocarcinoma of &lt;/= 3 cm: accuracy and interobserver agreement</article-title>
            <source>Histopathology</source>
            <year>2015</year>
            <volume>66</volume>
            <fpage>922</fpage>
            <lpage>938</lpage>
            <pub-id pub-id-type="doi">10.1111/his.12468</pub-id>
            <pub-id pub-id-type="pmid">24889415</pub-id>
            <pub-id pub-id-type="pmcid">PMC4536823</pub-id>
          </element-citation>
        </ref>
        <ref id="CR19">
          <label>19.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Vaghjiani</surname>
                <given-names>RG</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Tumor spread through air spaces is a predictor of occult lymph node metastasis in clinical stage IA lung adenocarcinoma</article-title>
            <source>J. Thorac. Oncol.</source>
            <year>2020</year>
            <volume>15</volume>
            <fpage>792</fpage>
            <lpage>802</lpage>
            <pub-id pub-id-type="doi">10.1016/j.jtho.2020.01.008</pub-id>
            <pub-id pub-id-type="pmid">32007599</pub-id>
            <pub-id pub-id-type="pmcid">PMC7199202</pub-id>
          </element-citation>
        </ref>
        <ref id="CR20">
          <label>20.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Bellomo</surname>
                <given-names>D</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Model combining tumor molecular and clinicopathologic risk factors predicts sentinel lymph node metastasis in primary cutaneous melanoma</article-title>
            <source>JCO Precis Oncol.</source>
            <year>2020</year>
            <volume>4</volume>
            <fpage>319</fpage>
            <lpage>334</lpage>
            <pub-id pub-id-type="doi">10.1200/PO.19.00206</pub-id>
            <pub-id pub-id-type="pmid">32405608</pub-id>
            <pub-id pub-id-type="pmcid">PMC7220172</pub-id>
          </element-citation>
        </ref>
        <ref id="CR21">
          <label>21.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Malkoski</surname>
                <given-names>SP</given-names>
              </name>
              <name name-style="western">
                <surname>Wang</surname>
                <given-names>XJ</given-names>
              </name>
            </person-group>
            <article-title>Two sides of the story? Smad4 loss in pancreatic cancer versus head-and-neck cancer</article-title>
            <source>FEBS Lett.</source>
            <year>2012</year>
            <volume>586</volume>
            <fpage>1984</fpage>
            <lpage>1992</lpage>
            <pub-id pub-id-type="doi">10.1016/j.febslet.2012.01.054</pub-id>
            <pub-id pub-id-type="pmid">22321641</pub-id>
            <pub-id pub-id-type="pmcid">PMC3285395</pub-id>
          </element-citation>
        </ref>
        <ref id="CR22">
          <label>22.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Massague</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>TGFbeta signalling in context</article-title>
            <source>Nat. Rev. Mol. Cell Biol.</source>
            <year>2012</year>
            <volume>13</volume>
            <fpage>616</fpage>
            <lpage>630</lpage>
            <pub-id pub-id-type="doi">10.1038/nrm3434</pub-id>
            <pub-id pub-id-type="pmid">22992590</pub-id>
            <pub-id pub-id-type="pmcid">PMC4027049</pub-id>
          </element-citation>
        </ref>
        <ref id="CR23">
          <label>23.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Haeger</surname>
                <given-names>SM</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Smad4 loss promotes lung cancer formation but increases sensitivity to DNA topoisomerase inhibitors</article-title>
            <source>Oncogene</source>
            <year>2016</year>
            <volume>35</volume>
            <fpage>577</fpage>
            <lpage>586</lpage>
            <pub-id pub-id-type="doi">10.1038/onc.2015.112</pub-id>
            <pub-id pub-id-type="pmid">25893305</pub-id>
            <pub-id pub-id-type="pmcid">PMC4615192</pub-id>
          </element-citation>
        </ref>
        <ref id="CR24">
          <label>24.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ziemke</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Patil</surname>
                <given-names>T</given-names>
              </name>
              <name name-style="western">
                <surname>Nolan</surname>
                <given-names>K</given-names>
              </name>
              <name name-style="western">
                <surname>Tippimanchai</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Malkoski</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer</article-title>
            <source>Lung Cancer</source>
            <year>2017</year>
            <volume>109</volume>
            <fpage>28</fpage>
            <lpage>35</lpage>
            <pub-id pub-id-type="doi">10.1016/j.lungcan.2017.04.017</pub-id>
            <pub-id pub-id-type="pmid">28577946</pub-id>
            <pub-id pub-id-type="pmcid">PMC5501281</pub-id>
          </element-citation>
        </ref>
        <ref id="CR25">
          <label>25.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Wilson</surname>
                <given-names>BG</given-names>
              </name>
              <name name-style="western">
                <surname>Roberts</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>SWI/SNF nucleosome remodellers and cancer</article-title>
            <source>Nat. Rev. Cancer</source>
            <year>2011</year>
            <volume>11</volume>
            <fpage>481</fpage>
            <lpage>492</lpage>
            <pub-id pub-id-type="doi">10.1038/nrc3068</pub-id>
            <pub-id pub-id-type="pmid">21654818</pub-id>
          </element-citation>
        </ref>
        <ref id="CR26">
          <label>26.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Helming</surname>
                <given-names>KC</given-names>
              </name>
              <name name-style="western">
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name name-style="western">
                <surname>Roberts</surname>
                <given-names>CWM</given-names>
              </name>
            </person-group>
            <article-title>Vulnerabilities of mutant SWI/SNF complexes in cancer</article-title>
            <source>Cancer Cell</source>
            <year>2014</year>
            <volume>26</volume>
            <fpage>309</fpage>
            <lpage>317</lpage>
            <pub-id pub-id-type="doi">10.1016/j.ccr.2014.07.018</pub-id>
            <pub-id pub-id-type="pmid">25203320</pub-id>
            <pub-id pub-id-type="pmcid">PMC4159614</pub-id>
          </element-citation>
        </ref>
        <ref id="CR27">
          <label>27.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Schoenfeld</surname>
                <given-names>AJ</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer</article-title>
            <source>Clin. Cancer Res.</source>
            <year>2020</year>
            <volume>26</volume>
            <fpage>5701</fpage>
            <lpage>5708</lpage>
            <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-1825</pub-id>
            <pub-id pub-id-type="pmid">32709715</pub-id>
            <pub-id pub-id-type="pmcid">PMC7641983</pub-id>
          </element-citation>
        </ref>
        <ref id="CR28">
          <label>28.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Rekhtman</surname>
                <given-names>N</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas</article-title>
            <source>J. Thorac. Oncol.</source>
            <year>2020</year>
            <volume>15</volume>
            <fpage>231</fpage>
            <lpage>247</lpage>
            <pub-id pub-id-type="doi">10.1016/j.jtho.2019.10.023</pub-id>
            <pub-id pub-id-type="pmid">31751681</pub-id>
            <pub-id pub-id-type="pmcid">PMC7556987</pub-id>
          </element-citation>
        </ref>
        <ref id="CR29">
          <label>29.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Qiu</surname>
                <given-names>T</given-names>
              </name>
              <name name-style="western">
                <surname>Guo</surname>
                <given-names>H</given-names>
              </name>
              <name name-style="western">
                <surname>Zhao</surname>
                <given-names>H</given-names>
              </name>
              <name name-style="western">
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name name-style="western">
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Next-generation sequencing for molecular diagnosis of lung adenocarcinoma specimens obtained by fine needle aspiration cytology</article-title>
            <source>Sci. Rep.</source>
            <year>2015</year>
            <volume>5</volume>
            <fpage>1</fpage>
            <lpage>7</lpage>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep11317</pub-id>
            <pub-id pub-id-type="pmcid">PMC4464150</pub-id>
            <pub-id pub-id-type="pmid">26066407</pub-id>
          </element-citation>
        </ref>
        <ref id="CR30">
          <label>30.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Bakhoum</surname>
                <given-names>SF</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Chromosomal instability drives metastasis through a cytosolic DNA response</article-title>
            <source>Nature</source>
            <year>2018</year>
            <volume>553</volume>
            <fpage>467</fpage>
            <lpage>472</lpage>
            <pub-id pub-id-type="doi">10.1038/nature25432</pub-id>
            <pub-id pub-id-type="pmid">29342134</pub-id>
            <pub-id pub-id-type="pmcid">PMC5785464</pub-id>
          </element-citation>
        </ref>
        <ref id="CR31">
          <label>31.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Motwani</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Pesiridis</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Fitzgerald</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>DNA sensing by the cGAS-STING pathway in health and disease</article-title>
            <source>Nat. Rev. Genet</source>
            <year>2019</year>
            <volume>20</volume>
            <fpage>657</fpage>
            <lpage>674</lpage>
            <pub-id pub-id-type="doi">10.1038/s41576-019-0151-1</pub-id>
            <pub-id pub-id-type="pmid">31358977</pub-id>
          </element-citation>
        </ref>
        <ref id="CR32">
          <label>32.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Gu</surname>
                <given-names>X</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Copy number variation: a prognostic marker for young patients with squamous cell carcinoma of the oral tongue</article-title>
            <source>J. Oral. Pathol. Med</source>
            <year>2019</year>
            <volume>48</volume>
            <fpage>24</fpage>
            <lpage>30</lpage>
            <pub-id pub-id-type="doi">10.1111/jop.12792</pub-id>
            <pub-id pub-id-type="pmid">30357923</pub-id>
            <pub-id pub-id-type="pmcid">PMC6587711</pub-id>
          </element-citation>
        </ref>
        <ref id="CR33">
          <label>33.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Hieronymus</surname>
                <given-names>H</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Copy number alteration burden predicts prostate cancer relapse</article-title>
            <source>Proc. Natl Acad. Sci. USA</source>
            <year>2014</year>
            <volume>111</volume>
            <fpage>11139</fpage>
            <lpage>11144</lpage>
            <pub-id pub-id-type="doi">10.1073/pnas.1411446111</pub-id>
            <pub-id pub-id-type="pmid">25024180</pub-id>
            <pub-id pub-id-type="pmcid">PMC4121784</pub-id>
          </element-citation>
        </ref>
        <ref id="CR34">
          <label>34.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name name-style="western">
                <surname>Feizi</surname>
                <given-names>N</given-names>
              </name>
              <name name-style="western">
                <surname>Chi</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Hu</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Association analysis of somatic copy number alteration burden with breast cancer survival</article-title>
            <source>Front. Genet.</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>421</fpage>
            <pub-id pub-id-type="doi">10.3389/fgene.2018.00421</pub-id>
            <pub-id pub-id-type="pmid">30337938</pub-id>
            <pub-id pub-id-type="pmcid">PMC6178888</pub-id>
          </element-citation>
        </ref>
        <ref id="CR35">
          <label>35.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Jones</surname>
                <given-names>GD</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>A genomic-pathologic annotated risk model to predict recurrence in early-stage lung adenocarcinoma: a prospective observational cohort study</article-title>
            <source>JAMA Surg.</source>
            <year>2021</year>
            <volume>156</volume>
            <fpage>e205601</fpage>
            <pub-id pub-id-type="doi">10.1001/jamasurg.2020.5601</pub-id>
            <pub-id pub-id-type="pmid">33355651</pub-id>
            <pub-id pub-id-type="pmcid">PMC7758824</pub-id>
          </element-citation>
        </ref>
        <ref id="CR36">
          <label>36.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Caso</surname>
                <given-names>R</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The underlying tumor genomics of predominant histologic subtypes in lung adenocarcinoma</article-title>
            <source>J. Thorac. Oncol.</source>
            <year>2020</year>
            <volume>15</volume>
            <fpage>1844</fpage>
            <lpage>1856</lpage>
            <pub-id pub-id-type="doi">10.1016/j.jtho.2020.08.005</pub-id>
            <pub-id pub-id-type="pmid">32791233</pub-id>
            <pub-id pub-id-type="pmcid">PMC7704768</pub-id>
          </element-citation>
        </ref>
        <ref id="CR37">
          <label>37.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Jamal-Hanjani</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Tracking the evolution of non-small-cell lung cancer</article-title>
            <source>N. Engl. J. Med.</source>
            <year>2017</year>
            <volume>376</volume>
            <fpage>2109</fpage>
            <lpage>2121</lpage>
            <pub-id pub-id-type="doi">10.1056/NEJMoa1616288</pub-id>
            <pub-id pub-id-type="pmid">28445112</pub-id>
          </element-citation>
        </ref>
        <ref id="CR38">
          <label>38.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Swanton</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>McGranahan</surname>
                <given-names>N</given-names>
              </name>
              <name name-style="western">
                <surname>Starrett</surname>
                <given-names>GJ</given-names>
              </name>
              <name name-style="western">
                <surname>Harris</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity</article-title>
            <source>Cancer Discov.</source>
            <year>2015</year>
            <volume>5</volume>
            <fpage>704</fpage>
            <lpage>712</lpage>
            <pub-id pub-id-type="doi">10.1158/2159-8290.CD-15-0344</pub-id>
            <pub-id pub-id-type="pmid">26091828</pub-id>
            <pub-id pub-id-type="pmcid">PMC4497973</pub-id>
          </element-citation>
        </ref>
        <ref id="CR39">
          <label>39.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Roper</surname>
                <given-names>N</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>APOBEC mutagenesis and copy-number alterations are drivers of proteogenomic tumor evolution and heterogeneity in metastatic thoracic tumors</article-title>
            <source>Cell Rep.</source>
            <year>2019</year>
            <volume>26</volume>
            <fpage>2651</fpage>
            <lpage>2666</lpage>
            <pub-id pub-id-type="doi">10.1016/j.celrep.2019.02.028</pub-id>
            <pub-id pub-id-type="pmid">30840888</pub-id>
            <pub-id pub-id-type="pmcid">PMC6461561</pub-id>
          </element-citation>
        </ref>
        <ref id="CR40">
          <label>40.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Jia</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>He</surname>
                <given-names>Z</given-names>
              </name>
              <name name-style="western">
                <surname>Liu</surname>
                <given-names>X-S</given-names>
              </name>
            </person-group>
            <article-title>APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer</article-title>
            <source>Oncogene</source>
            <year>2018</year>
            <volume>37</volume>
            <fpage>3924</fpage>
            <lpage>3936</lpage>
            <pub-id pub-id-type="doi">10.1038/s41388-018-0245-9</pub-id>
            <pub-id pub-id-type="pmid">29695832</pub-id>
            <pub-id pub-id-type="pmcid">PMC6053356</pub-id>
          </element-citation>
        </ref>
        <ref id="CR41">
          <label>41.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Bielski</surname>
                <given-names>CM</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Genome doubling shapes the evolution and prognosis of advanced cancers</article-title>
            <source>Nat. Genet</source>
            <year>2018</year>
            <volume>50</volume>
            <fpage>1189</fpage>
            <lpage>1195</lpage>
            <pub-id pub-id-type="doi">10.1038/s41588-018-0165-1</pub-id>
            <pub-id pub-id-type="pmid">30013179</pub-id>
            <pub-id pub-id-type="pmcid">PMC6072608</pub-id>
          </element-citation>
        </ref>
        <ref id="CR42">
          <label>42.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing</article-title>
            <source>Science</source>
            <year>2014</year>
            <volume>346</volume>
            <fpage>256</fpage>
            <lpage>259</lpage>
            <pub-id pub-id-type="doi">10.1126/science.1256930</pub-id>
            <pub-id pub-id-type="pmid">25301631</pub-id>
            <pub-id pub-id-type="pmcid">PMC4354858</pub-id>
          </element-citation>
        </ref>
        <ref id="CR43">
          <label>43.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Isaka</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Comparison of clinically relevant mutation profiles between preoperative biopsy and corresponding surgically resected specimens in japanese patients with non–small-cell lung cancer by amplicon-based massively parallel sequencing</article-title>
            <source>Clin. Lung Cancer</source>
            <year>2017</year>
            <volume>18</volume>
            <fpage>519</fpage>
            <lpage>526</lpage>
            <pub-id pub-id-type="doi">10.1016/j.cllc.2016.11.022</pub-id>
            <pub-id pub-id-type="pmid">28057436</pub-id>
          </element-citation>
        </ref>
        <ref id="CR44">
          <label>44.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Kage</surname>
                <given-names>H</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Small lung tumor biopsy samples are feasible for high quality targeted next generation sequencing</article-title>
            <source>Cancer Sci.</source>
            <year>2019</year>
            <volume>110</volume>
            <fpage>2652</fpage>
            <pub-id pub-id-type="doi">10.1111/cas.14112</pub-id>
            <pub-id pub-id-type="pmid">31222846</pub-id>
            <pub-id pub-id-type="pmcid">PMC6676108</pub-id>
          </element-citation>
        </ref>
        <ref id="CR45">
          <label>45.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Imielinski</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing</article-title>
            <source>Cell</source>
            <year>2012</year>
            <volume>150</volume>
            <fpage>1107</fpage>
            <lpage>1120</lpage>
            <pub-id pub-id-type="doi">10.1016/j.cell.2012.08.029</pub-id>
            <pub-id pub-id-type="pmid">22980975</pub-id>
            <pub-id pub-id-type="pmcid">PMC3557932</pub-id>
          </element-citation>
        </ref>
        <ref id="CR46">
          <label>46.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Cheng</surname>
                <given-names>DT</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology</article-title>
            <source>J. Mol. Diagn.</source>
            <year>2015</year>
            <volume>17</volume>
            <fpage>251</fpage>
            <lpage>264</lpage>
            <pub-id pub-id-type="doi">10.1016/j.jmoldx.2014.12.006</pub-id>
            <pub-id pub-id-type="pmid">25801821</pub-id>
            <pub-id pub-id-type="pmcid">PMC5808190</pub-id>
          </element-citation>
        </ref>
        <ref id="CR47">
          <label>47.</label>
          <mixed-citation publication-type="other">National Comprehensive Cancer Network. <italic toggle="yes">Non-Small Cell Lung Cancer (Version 7.2019)</italic>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1450">https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1450</ext-link>. (2019).</mixed-citation>
        </ref>
        <ref id="CR48">
          <label>48.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Zhou</surname>
                <given-names>J</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Analysis of tumor genomic pathway alterations using broad-panel next generation sequencing in surgically resected lung adenocarcinoma</article-title>
            <source>Clin. Cancer Res.</source>
            <year>2019</year>
            <volume>25</volume>
            <fpage>7475</fpage>
            <lpage>7484</lpage>
            <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-1651</pub-id>
            <pub-id pub-id-type="pmid">31455678</pub-id>
            <pub-id pub-id-type="pmcid">PMC6911636</pub-id>
          </element-citation>
        </ref>
        <ref id="CR49">
          <label>49.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Shen</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Seshan</surname>
                <given-names>VE</given-names>
              </name>
            </person-group>
            <article-title>FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing</article-title>
            <source>Nucleic Acids Res.</source>
            <year>2016</year>
            <volume>44</volume>
            <fpage>e131</fpage>
            <pub-id pub-id-type="doi">10.1093/nar/gkw520</pub-id>
            <pub-id pub-id-type="pmid">27270079</pub-id>
            <pub-id pub-id-type="pmcid">PMC5027494</pub-id>
          </element-citation>
        </ref>
        <ref id="CR50">
          <label>50.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Mermel</surname>
                <given-names>CH</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers</article-title>
            <source>Genome Biol.</source>
            <year>2011</year>
            <volume>12</volume>
            <fpage>R41</fpage>
            <pub-id pub-id-type="doi">10.1186/gb-2011-12-4-r41</pub-id>
            <pub-id pub-id-type="pmid">21527027</pub-id>
            <pub-id pub-id-type="pmcid">PMC3218867</pub-id>
          </element-citation>
        </ref>
        <ref id="CR51">
          <label>51.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Alexandrov</surname>
                <given-names>LB</given-names>
              </name>
              <name name-style="western">
                <surname>Nik-Zainal</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Wedge</surname>
                <given-names>DC</given-names>
              </name>
              <name name-style="western">
                <surname>Campbell</surname>
                <given-names>PJ</given-names>
              </name>
              <name name-style="western">
                <surname>Stratton</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Deciphering signatures of mutational processes operative in human cancer</article-title>
            <source>Cell Rep.</source>
            <year>2013</year>
            <volume>3</volume>
            <fpage>246</fpage>
            <lpage>259</lpage>
            <pub-id pub-id-type="doi">10.1016/j.celrep.2012.12.008</pub-id>
            <pub-id pub-id-type="pmid">23318258</pub-id>
            <pub-id pub-id-type="pmcid">PMC3588146</pub-id>
          </element-citation>
        </ref>
        <ref id="CR52">
          <label>52.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Zehir</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients</article-title>
            <source>Nat. Med.</source>
            <year>2017</year>
            <volume>23</volume>
            <fpage>703</fpage>
            <pub-id pub-id-type="doi">10.1038/nm.4333</pub-id>
            <pub-id pub-id-type="pmid">28481359</pub-id>
            <pub-id pub-id-type="pmcid">PMC5461196</pub-id>
          </element-citation>
        </ref>
        <ref id="CR53">
          <label>53.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Alexandrov</surname>
                <given-names>LB</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The repertoire of mutational signatures in human cancer</article-title>
            <source>Nature</source>
            <year>2020</year>
            <volume>578</volume>
            <fpage>94</fpage>
            <lpage>101</lpage>
            <pub-id pub-id-type="doi">10.1038/s41586-020-1943-3</pub-id>
            <pub-id pub-id-type="pmid">32025018</pub-id>
            <pub-id pub-id-type="pmcid">PMC7054213</pub-id>
          </element-citation>
        </ref>
        <ref id="CR54">
          <label>54.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Cerami</surname>
                <given-names>E</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data</article-title>
            <source>Cancer Discov.</source>
            <year>2012</year>
            <volume>2</volume>
            <fpage>401</fpage>
            <lpage>404</lpage>
            <pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0095</pub-id>
            <pub-id pub-id-type="pmid">22588877</pub-id>
            <pub-id pub-id-type="pmcid">PMC3956037</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </article>
</pmc-articleset>
